# ImmunityBio Shares Track Weekly Loss Despite Early FDA Approval for Anktiva

- URL: https://stocks.freetheai.org/news/immunitybio-shares-track-weekly-loss-despite-early-fda-approval-for-anktiva-0c4a18
- Published: 2026-10-15T01:29:48Z
- Category: company_news; sentiment: mixed; impact: medium
- Symbols: [NASDAQ:IBRX](https://stocks.freetheai.org/symbols/NASDAQ-IBRX)
- Written by our AI from expert market sources across the web for FreeTheAI Stocks, built by Vibhek Soni
- How write-ups are made: https://stocks.freetheai.org/how-we-write
- Not financial advice: https://stocks.freetheai.org/disclaimer

ImmunityBio Inc (IBRX) gained expanded U.S. Food and Drug Administration approval for its immunotherapy drug Anktiva to treat adults with BCG-unresponsive non-muscle-invasive bladder cancer featuring papillary-only tumors. The decision arrived nearly three months ahead of the planned target decision date. On Wednesday, the stock rose 1.12% to close at $9.91, though shares remain on track for a 6% weekly decline.

The regulatory expansion broadens Anktiva's reach, as papillary disease represents approximately 85% of non-muscle-invasive bladder cancer cases. Combined with Bacillus Calmette-Guerin, Anktiva becomes the first FDA-approved therapy specifically for papillary-only disease in this patient group. The regimen previously received a Category 2A recommendation in medical guidelines earlier this year and holds regulatory authorizations across 34 countries.

Investors are focusing on an upcoming Friday discussion where founder Patrick Soon-Shiong will discuss ongoing clinical trials, including the QUILT-2.005 study evaluating Anktiva in patients who have not previously received BCG. The company plans to submit a supplemental regulatory application for BCG-naive patients in 2026.

## Key points

- The FDA expanded Anktiva's approval to cover BCG-unresponsive bladder cancer with papillary-only tumors almost three months ahead of schedule.
- Papillary disease accounts for about 85% of non-muscle-invasive bladder cancer cases, expanding Anktiva's U.S. patient population.
- ImmunityBio stock rose 1.12% on Wednesday to close at $9.91 but remains down 6% for the week.
- Founder Patrick Soon-Shiong is set to discuss clinical trial status during a fireside chat on Friday.
- ImmunityBio plans to submit a supplemental application for BCG-naive bladder cancer patients in 2026.

## Questions and answers

### What is the new FDA approval for ImmunityBio Anktiva?

The FDA expanded approval for Anktiva to treat adults with BCG-unresponsive non-muscle-invasive bladder cancer who have papillary-only tumors, administered alongside BCG.

### Why is ImmunityBio stock down despite the FDA decision?

Despite gaining early regulatory approval and closing 1.12% higher on Wednesday at $9.91, ImmunityBio stock remains down 6% for the week as investors await further clinical trial updates.

### When will ImmunityBio provide its next clinical trial update?

Founder Patrick Soon-Shiong is scheduled to discuss the status of clinical trials during a fireside chat on Friday.